Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results...
(Source: Cynapsus Therapeutics Inc) -- Webcast with accompanying slides to discuss these findings tomorrow at 7:30 a.m. Eastern time Top-line CTH-300 results expected in late Q3 or early Q4 -- TORONTO,...
View ArticleGilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets...
(Source: Gilead Sciences Inc) FOSTER CITY, Calif.--(BUSINESS WIRE)--Jul. 21, 2016-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that two Phase 3b switch studies evaluating Odefsey...
View ArticleAcceleron Announces ACE-083 Phase 1 Results at the 14th International...
Acceleron Announces ACE-083 Phase 1 Results at the 14th International Congress on Neuromuscular Diseases -ACE-083 increased muscle volume of the tibialis anterior muscle by 8.9% in healthy volunteers-...
View ArticleCynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results...
-- Webcast with accompanying slides to discuss these findings tomorrow at 7:30 a.m. Eastern time Top-line CTH-300 results expected in late Q3 or early Q4 -- TORONTO, July 18, 2016 (GLOBE NEWSWIRE) --...
View Article07/07/2016 ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY...
(Source: Ablynx NV) 7774bf26-b185-44c3-b7a5-30f44b343fd8.pdf ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY OF ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB (ALX-0061), AS A MONOTHERAPY IN...
View ArticleBrainStorm Announces Positive Top Line Results from the U.S. Phase 2 Study of...
(Source: Brainstorm Cell Therapeutics Inc) HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 18, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem...
View ArticleGilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets...
Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies Gilead Sciences, Inc. (Nasdaq:GILD) today announced that two Phase 3b...
View ArticleBristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA®...
(Source: Bristol-Myers Squibb Company) PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today the commercial launch of the ORENCIA ClickJect Autoinjector, a new...
View ArticleSpring Bank Pharmaceuticals Doses the First Patient in the ACHIEVE Global...
(Source: Spring Bank Pharmaceuticals Inc) HOPKINTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing...
View ArticleSanofi and Regeneron Announce Approval of Praluent® (alirocumab) for the...
(Source: Sanofi SA) Paris, France and Tarrytown, New York - July 5, 2016-Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the Ministry of Health, Labor and Welfare in Japan has granted...
View ArticleCardioprotective Interventions: Where Are We? (American College of Cardiology...
(Source: American College of Cardiology Foundation) Cardiotoxicity is a well-recognized complication of chemotherapeutic agents. Cardiotoxicity encompasses multiple effects including subclinical...
View ArticleReata Pharmaceuticals, Inc. Announces Interim Data From Extension Phase 2...
(Source: Reata Pharmaceuticals Inc) IRVING, Texas, June 23, 2016 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA) ('Reata'), a clinical-stage biopharmaceutical company, today announced...
View ArticleVery strong performance in the first half of 2016 - enhanced by successful...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 21 July 2016- Actelion Ltd (SIX: ATLN) today announced its results for the first six months of 2016. OPERATING HIGHLIGHTS Excellent Opsumit...
View ArticleHerantis Pharma receives orphan designation in USA for CDNF for treatment of...
(Source: Herantis Pharma Oyj) Herantis Pharma receives orphan designation in USA for CDNF for treatment of ALS Herantis Pharma Plc Company release 11 July 2016 at 9:00 am The United States Food and...
View ArticleLilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in...
(Source: Eli Lilly and Company) INDIANAPOLIS, July 13, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced a new collaboration on a Phase 1b study that will...
View ArticleActelion (ALIOF) Beats Q2 Earnings & Revenues, View Up
Actelion Ltd. ALIOF reported second-quarter 2016 earnings of $2.13 per American Depository Receipt (ADR), up from the year-ago figure of $1.60. Reported earnings were also above the Zacks Consensus...
View ArticleAnavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in...
Results Feature Favorable Safety, Maximum Tolerated Dose, Positive Dose Response as well as Positive Unexpected Therapeutic Response Events NEW YORK, July 24, 2016 (GLOBE NEWSWIRE) -- Anavex Life...
View ArticleAlder Reports Positive Top-Line 24-Week Data Demonstrating Persistent...
(Source: Alder Biopharmaceuticals Inc) BOTHELL, Wash., July 25, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal...
View ArticleBellerophon Receives Approval to Commence Phase 2 Trial in PH-COPD...
(Source: Bellerophon Therapeutics Inc) -- Trial expected to commence in third quarter; Results to be reported by year end 2016 -- -- Previous data supporting testing long-term benefits of pulsed...
View ArticleMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and...
(Source: MediciNova Inc) LA JOLLA, Calif., July 24, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the...
View Article